Celera Seeks Approval For Coronary Heart Disease Genoytyping Assay
This article was originally published in The Gray Sheet
Executive Summary
Celera is seeking FDA approval for a genetic assay to detect risk of coronary heart disease, including potential use as a therapy guide for the 20-30 million Americans who are being considered for treatment with statin drugs such as Lipitor.